文献速递呼吸道感染呼吸危重症与机械通气

COVID-19急性呼吸窘迫综合征患者固有免疫失控与适应性免疫受损

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

前瞻性观察性单中心研究比较COVID-19 ARDS与非COVID-19 ARDS患者免疫病理差异,发现COVID-19患者存在持续T细胞和B细胞减少及特定趋化因子升高,且CXCL10/IP-10和GM-CSF升高及鼻咽病毒载量高与28天死亡率相关。

要点

  • COVID-19 ARDS患者28天死亡率高于非COVID-19 ARDS(34% vs 11%,P=0.030)。
  • COVID-19患者表现持续CD4+、CD8+和B细胞减少及单核细胞HLA-DR表达升高。
  • 血清CXCL10/IP-10和GM-CSF升高及鼻咽病毒载量高与28天死亡相关。

核心结论

  • COVID-19 ARDS以显著全系淋巴细胞减少和趋化因子特征为特点,CXCL10/IP-10和GM-CSF升高及病毒载量高与28天死亡率相关。

研究设计与样本

  • 前瞻性观察性单中心研究,纳入2020年3月8日至3月30日RT-PCR确诊SARS-CoV-2感染并ARDS的免疫功能正常患者38例,与非COVID-19 ARDS患者36例比较,主要终点为28天死亡率。

主要发现

  • COVID-19患者较非COVID-19 ARDS患者28天死亡率更高(34% vs 11%,P=0.030)。
  • COVID-19患者存在持续CD4+(P=0.002)、CD8+(P<0.0001)和B细胞(P<0.0001)减少,单核细胞HLA-DR表达更高(P<0.001)。
  • COVID-19患者血清EGF、GM-CSF、IL-10、CCL2/MCP-1、CCL3/MIP-1a、CXCL10/IP-10、CCL5/RANTES和CCL20/MIP-3a浓度更高。
  • 调整年龄和SOFA评分后,28天死亡COVID-19患者血清CXCL10/IP-10(P=0.047)和GM-CSF(P=0.050)更高,鼻咽RT-PCR循环阈值更低(P=0.010)。

临床怎么用

  • 监测COVID-19 ARDS患者淋巴细胞亚群及血清CXCL10/IP-10、GM-CSF水平可能有助于死亡风险分层。
  • 鼻咽SARS-CoV-2病毒载量高(低Ct值)提示28天死亡风险增加。

局限性

  • 单中心前瞻性观察性研究,样本量较小(COVID-19组38例,非COVID-19组36例),结果需多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Uncontrolled inflammatory innate response and impaired adaptive immune response are associated with clinical severity in patients with coronavirus disease (COVID-19).Objectives: To compare the immunopathology of COVID-19 acute respiratory distress syndrome (ARDS) with that of non-COVID-19 ARDS, and to identify biomarkers associated with mortality in patients with COVID-19 ARDS.Methods: Prospective observational monocenter study. Immunocompetent patients diagnosed with RT-PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and ARDS admitted between March 8 and March 30, 2020, were included and compared with patients with non-COVID-19 ARDS. The primary clinical endpoint of the study was mortality at Day 28. Flow cytometry analyses and serum cytokine measurements were performed at Days 1-2 and 4-6 of ICU admission.Measurements and Main Results: As compared with patients with non-COVID-19 ARDS (n = 36), those with COVID-19 (n = 38) were not significantly different regarding age, sex, and Sequential Organ Failure Assessment and Simplified Acute Physiology Score II scores but exhibited a higher Day-28 mortality (34% vs. 11%, P = 0.030). Patients with COVID-19 showed profound and sustained T CD4+ (P = 0.002), CD8+ (P < 0.0001), and B (P < 0.0001) lymphopenia, higher HLA-DR expression on monocytes (P < 0.001) and higher serum concentrations of EGF (epithelial growth factor), GM-CSF, IL-10, CCL2/MCP-1, CCL3/MIP-1a, CXCL10/IP-10, CCL5/RANTES, and CCL20/MIP-3a. After adjusting on age and Sequential Organ Failure Assessment, serum CXCL10/IP-10 (P = 0.047) and GM-CSF (P = 0.050) were higher and nasopharyngeal RT-PCR cycle threshold values lower (P = 0.010) in patients with COVID-19 who were dead at Day 28.Conclusions: Profound global lymphopenia and a "chemokine signature" were observed in COVID-19 ARDS. Increased serum concentrations of CXCL10/IP-10 and GM-CSF, together with higher nasopharyngeal SARS-CoV-2 viral load, were associated with Day-28 mortality.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Hue S, Beldi-Ferchiou A, Bendib I, et al. Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020. PMID: 32866033. doi:10.1164/rccm.202005-1885OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。